UNSPSC 51412007: Ipramidil

This classification denotes a vasodilating agent with the molecular formula C10H16N4O4, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 9ZPC9768EH, chemically known as n,n-diisopropyl-3,4-furazandicarboxamide 2-oxide but generally known as ipramidil, which bears US NIH Compound Identifier 71268. European Medicines Agency schedules Ipramidil in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB08275MIG.

UNSPSC 51412007 Ipramidil is a Commodity code covering vasodilator medications supplied to state and local government health and emergency services. State and local buyers use this code to procure prescription pharmaceuticals—specifically ipramidol and related vasodilators—for emergency medical services, hospital systems, and health agency formularies. The solicitations show that municipalities and state health agencies are actively buying advanced life support medications (including vasodilators) through formal competitive bids and cooperative purchasing arrangements, often as part of broader multi-drug procurements serving fire rescue services, pharmacy benefit programs, and multi-jurisdictional government health plans. Issuing bodies span city purchasing departments (Tampa), state health commissions (Texas HHS), and regional cooperative purchasing alliances (Minnesota MMCAP), with the cooperative purchasing model emerging as a significant aggregation mechanism that bundles pharmaceuticals across multiple state and local members.

Recent activity includes the City of Tampa's IFB for Advanced Life Support Medications (Solicitation 26P00188, due April 8, 2026, estimated value $40,000) supplying Tampa Fire Rescue with vasodilators and other cardiac medications; the Texas Health and Human Services Commission's RFI (HHS0017013, posted April 3, 2026) exploring direct-to-manufacturer prescription programs that would affect state pharmacy benefit procurement; and MMCAP's RFP for generic multi-source pharmaceuticals (S1070000015802, due March 26, 2026) serving multiple state and local facilities across Minnesota and Oregon through authorized wholesalers. Geographic activity centers on Florida, Texas, and the Upper Midwest, with cooperative purchasing extending the reach across multiple state jurisdictions. Recent opportunities show price competitiveness, compliance with cGMP and federal drug supply chain security standards, and wholesale distribution through established pharmaceutical channels as baseline qualifications; set-asides vary by issuing body, with Tampa's small local business enterprise designation at 5 percent but MMCAP procurements not specifying disadvantaged enterprise restrictions in available documentation.